GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
GO:004573222 | Liver | HCC | positive regulation of protein catabolic process | 163/7958 | 231/18723 | 4.00e-18 | 4.69e-16 | 163 |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:004586222 | Liver | HCC | positive regulation of proteolysis | 232/7958 | 372/18723 | 5.66e-15 | 3.98e-13 | 232 |
GO:001619721 | Liver | HCC | endosomal transport | 154/7958 | 230/18723 | 4.74e-14 | 2.95e-12 | 154 |
GO:001703811 | Liver | HCC | protein import | 140/7958 | 206/18723 | 1.12e-13 | 6.46e-12 | 140 |
GO:000703211 | Liver | HCC | endosome organization | 61/7958 | 82/18723 | 4.36e-09 | 1.15e-07 | 61 |
GO:003250611 | Liver | HCC | cytokinetic process | 32/7958 | 39/18723 | 4.73e-07 | 7.69e-06 | 32 |
GO:000028111 | Liver | HCC | mitotic cytokinesis | 51/7958 | 71/18723 | 5.20e-07 | 8.38e-06 | 51 |
GO:000091011 | Liver | HCC | cytokinesis | 100/7958 | 173/18723 | 3.38e-05 | 3.39e-04 | 100 |
GO:190382811 | Liver | HCC | negative regulation of cellular protein localization | 71/7958 | 117/18723 | 5.44e-05 | 5.12e-04 | 71 |
GO:003010021 | Liver | HCC | regulation of endocytosis | 117/7958 | 211/18723 | 9.56e-05 | 8.32e-04 | 117 |
GO:006164011 | Liver | HCC | cytoskeleton-dependent cytokinesis | 60/7958 | 100/18723 | 3.09e-04 | 2.20e-03 | 60 |
GO:00065091 | Liver | HCC | membrane protein ectodomain proteolysis | 28/7958 | 43/18723 | 2.30e-03 | 1.14e-02 | 28 |
GO:003361911 | Liver | HCC | membrane protein proteolysis | 35/7958 | 57/18723 | 3.08e-03 | 1.43e-02 | 35 |
GO:00069071 | Liver | HCC | pinocytosis | 16/7958 | 22/18723 | 4.03e-03 | 1.76e-02 | 16 |
GO:000989620 | Oral cavity | OSCC | positive regulation of catabolic process | 307/7305 | 492/18723 | 2.29e-26 | 7.64e-24 | 307 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNX33 | SNV | Missense_Mutation | | c.1559G>A | p.Cys520Tyr | p.C520Y | Q8WV41 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
SNX33 | SNV | Missense_Mutation | novel | c.805N>G | p.His269Asp | p.H269D | Q8WV41 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
SNX33 | SNV | Missense_Mutation | | c.656G>A | p.Arg219His | p.R219H | Q8WV41 | protein_coding | tolerated(0.54) | benign(0.223) | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SNX33 | insertion | In_Frame_Ins | novel | c.803_804insGGCTGCTAAGGGAGGAGG | p.Lys268_His269insAlaAlaLysGlyGlyGly | p.K268_H269insAAKGGG | Q8WV41 | protein_coding | | | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
SNX33 | insertion | Nonsense_Mutation | novel | c.695_696insAGCCCAGCTAGGAGTGGTGGGGGCAGTGGCTTCCT | p.Cys232Ter | p.C232* | Q8WV41 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | novel | c.5N>T | p.Ala2Val | p.A2V | Q8WV41 | protein_coding | deleterious(0) | possibly_damaging(0.516) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SNX33 | SNV | Missense_Mutation | rs765176187 | c.524N>A | p.Arg175Gln | p.R175Q | Q8WV41 | protein_coding | tolerated(0.25) | benign(0.06) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | | c.1593G>T | p.Met531Ile | p.M531I | Q8WV41 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | | c.797N>A | p.Arg266His | p.R266H | Q8WV41 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3667-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX33 | SNV | Missense_Mutation | | c.1146G>T | p.Lys382Asn | p.K382N | Q8WV41 | protein_coding | deleterious(0.01) | benign(0.444) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |